The MHRA has approved depemokimab as an add on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

Monthly Tezepelumab injections helped 90% of severe asthma patients cut steroid use, with many seeing improved symptoms and fewer ER visits.

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

Scientists found that RSV infection early in life can set the stage for childhood asthma, particularly in kids already genetically prone to allergies. The virus appears to skew the developing immune ...

In the 12 months after starting tezepelumab, patients with severe asthma had fewer exacerbations, a lower cumulative oral ...

The updated asthma diagnosis pathway places stronger emphasis on FeNO testing and structured clinical assessment.

December 16 is National Chocolate-Covered Anything Day, which is either a celebration of culinary creativity or an excuse to ...

The number of pediatric ED visits and hospital admissions with an asthma diagnosis was higher after vs. before the COVID-19 pandemic, according to study findings.These data were presented at the ...